Celcuity

Scientific Posters & Publications

Drug development backed by sound research

Below are a sample of innovative research published and presented by our team and our collaborators.

Filter by Cancer Type:

June 2026
A randomized, open-label, phase 3 study of gedatolisib + fulvestrant ± palbociclib vs standard of care in HR+/HER2−/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 Study 2)

Sara A. Hurvitz, Giuseppe Curigliano, Fabrice Andre, Rachel M. Layman, Robert Wesolowski, Massimo Cristofanilli, Miguel Martin, Alistair E. Ring, Juan Manuel Puig,Martin E. Richardet, Junghoon Shin, Sung-Bae Kim, Liang-Chih Liu, Geronimo Rosselli, Sarah Mutka, Alex Cacovean, Samuel Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli

2026 American Society of Clinical Oncology (ASCO) Annual Meeting
March 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, MD, Rachel M. Layman, MD, Giuseppe Curigliano, MD, PhD, Fabrice André, MD, PhD, Massimo Cristofanilli, MD, Sung-Bae Kim, MD, PhD, Jorge Luis Martínez Rodríguez, MD, Jorge C. Nadal, MD, Gun Min Kim, MD, Louisa Lo, MD, PhD, Yuly A. Remolina-Bonilla, MD, Geronimo Rosselli, MD, George Emile, MD, Ernesto Korbenfeld, MD, Juan Manuel Puig, MD, Robert Wesolowski, MD, Miguel Martin, MD, PhD, Alistair Ring, MD, Hyo S. Han, MD, Antonio Giordano, MD, PhD, Sarah C. Mutka, PhD, Keren Moss, MD, Sam Suzuki, MS, Brian Sullivan, AB, Igor Gorbatchevsky, MD, Barbara Pistilli, MD

Journal of Clinical Oncology
December 2025
Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy

Salmaan Khan, Jhomary Molden, Charles Iversrud, Donna Mattonen, Stefano Rossetti* and Lance Laing

International Journal of Molecular Sciences
December 2025
Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models adapted to estrogen receptor and/or CDK4/6 inhibitors

Stefano Rossetti, Aaron Broege, Laura Davis, Megan Seibel, Sydney Stokke, Jhomary Molden, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2025 San Antonio Breast Cancer Symposium (SABCS)
December 2025
Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, plus fulvestrant with or without palbociclib for second-line treatment of patients with HR+/HER2-/ PIK3CA-WT advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial

Barbara Pistilli, Rachel M. Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Miguel Martin, Robert Wesolowski, Sung-Bae Kim, Gun Min Kim, Martin E. Richardet, Jorge Carlos Nadal, Alistair Ring, Jorge Luis Martínez Rodríguez, Hyo S. Han, Antonio Giordano, Keren Moss, Sarah C. Mutka, Brian Sullivan, Samuel Suzuki, Igor Gorbatchevsky, Sara A. Hurvitz

2025 San Antonio Breast Cancer Symposium (SABCS)
2025
Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Alice Bernard-Tessier, Adam Sharp, Josep Maria M. Piulats, Jorge Esteban Villarrubia, Frank Cackowski, Hakim Mahammedi, Sara Perez Ramirez,7 David Lorente, Delphine Borchiellini, Gwenaelle Gravis, Michael Nessly, Sarah Mutka, Alex Cacovean, Igor Gorbatchevsky

2025 European Society for Medical Oncology (ESMO)
2025
Gedatolisib Plus Fulvestrant, With & Without Palbociclib, vs Fulvestrant in Patients With HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer: First Results from VIKTORIA-1

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Martin Richardet, Jorge Luis Martínez Rodríguez, Jorge Carlos Nadal, Gun Min Kim, George Emile, Robert Wesolowski, Miguel Martin, Alistair Ring, Sarah C. Mutka, Samuel Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli

2025 European Society for Medical Oncology (ESMO)
2025
Gedatolisib combined with palbociclib and letrozole in patients with no prior systemic therapy for hormone receptor–positive, HER2-negative advanced breast cancer

Robert Wesolowski, Hope S. Rugo, Jennifer M. Specht, Hyo S. Han, Peter Kabos, Ulka Vaishampayan, Seth A. Wander, Keerthi Gogineni, Alexander Spira, Anne F. Schott, Maysa Abu-Khalaf, Sarah C. Mutka, Samuel Suzuki, Brian Sullivan, Igor Gorbatchevsky, and Rachel M. Layman

Clinical Cancer Research
2025
Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

Hope S. Rugo, Robert Wesolowski, Hyo Han, Jennifer M. Specht, E. Claire Dees, Erica M. Stringer-Reasor, Peter Kabos, Vandana Abramson, Amy Weise, Anne Schott, Maysa Abu-Khalaf, Keerthi Gogineni, Alexander Spira, Charlotte Moser, Nadene Zack, Samuel Suzuki, Sarah Mutka, Brian Sullivan, Igor Gorbatchevsky, Rachel M. Layman

The Lancet Oncology
2025
Functional analysis of the PI3K/AKT/mTOR pathway inhibitor, gedatolisib, plus fulvestrant with and without palbociclib in breast cancer models

Aaron Broege, Stefano Rossetti, Adrish Sen, Ann De La Forest, Laura Davis, Megan Seibel, Arul Menon, Syndey Stokke, Allison Macaulay, Jhomary Molden, Lance Laing

International Journal of Molecular Sciences
2024
Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

Hope S. Rugo, Robert Wesolowski, Hyo Han, Jennifer M. Specht, E. Claire Dees, Erica M. Stringer-Reasor, Peter Kabos, Vandana Abramson, Amy Weise, Anne Schott, Maysa Abu-Khalaf, Keerthi Gogineni, Alexander Spira, Charlotte Moser, Nadene Zack, Samuel Suzuki, Sarah Mutka, Brian Sullivan, Igor Gorbatchevsky, Rachel M. Layman

2024 San Antonio Breast Cancer Symposium (SABCS)
2024
Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions

Stefano Rossetti, Aaron Broege, Jhomary Molden, Ross Kopher, Stephen Schulz, Ky McCracken, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2024 San Antonio Breast Cancer Symposium (SABCS)
2024
Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models

Stefano Rossetti, Aaron Broege, Megan Seibel, Jhomary Molden, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2024 San Antonio Breast Cancer Symposium (SABCS)
2024
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib

Aaron Broege, Stefano Rossetti, Adrish Sen, Aurul Menon, Ian MacNeil, Jhomary Molden, and Lance Laing

Cancers
2024
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway

Adrish Sen, Salmaan Khan, Stefano Rossetti , Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz and Lance Laing

Molecular Oncology